CLIA NT-proBNP

Chemiluminescence kit for the detection of Nt-proBNP in human serum and heparine plasma.

Coming soon
Catalog Number: CL-NTpBNP100
Size: 100 tests
Regulatory status: CE IVD
Clinical topic: Cardiovascular Diseases & Salt Metabolism
CLIA NT-proBNP
  • Screen for heart failure risk
  • Diagnose heart failure
  • Help predict outcomes in patients with heart failure
  • Help guide pharmacologic treatment of patients with heart failure

NT-proBNP concentration is a quantitative plasma biomarker for the presence and severity of hemodynamic cardiac stress and heart failure (HF). Current guidelines for the diagnosis and management of heart failure recommend the use of NT-proBNP as an established biomarker for HF diagnosis, therapy monitoring, and prognosis and implemented it in algorithms for the diagnosis and treatment of HF. The measurement NT-proBNP is helpful in screening to identify or exclude cardiac disease and is also a robust powerful prognostic tool. It can help clinicians to establish the differential diagnosis of symptoms that might be due to HF and manage patients in several clinical scenarios.

Diagnosis of Heart Failure
The most common presentation of HF is dyspnea and fatigue, complaints that are neither specific nor sensitive for predicting the presence of HF. NT-proBNP is an essential initial investigation to improve diagnostic accuracy and facilitate early diagnosis or the early exclusion of HF in both acute and non-acute settings.

Risk Stratification and Outcome Prediction
Measurement of NT-proBNP is useful to establish a prognosis of disease severity in chronic HF. On admission to the hospital, it is useful for prognosis in acutely decompensated HF. During an HF hospitalization, a predischarge NT-proBNP level can be used to establish a postdischarge prognosis.

Monitoring and prevention
NT-proBNP biomarker is also utilized in CHF disease and treatment monitoring and new data suggest that NT-proBNP screen and early intervention may prevent HF.

Technical specifications

Technical data
References

Technical data

Assay time25 min
Assay stability (on board)30 days
Sample matrix Serum, Plasma-Heparin
Sample volume40 µL
Sample stability7 days at 2-8 °C, 24 months at -20 °C
Concentration range125 – 8000 pg/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions

References

References to CLIA NT-proBNP

  • Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019 Jun;21(6):715-731. doi: 10.1002/ejhf.1494. PMID: 31222929.
    See more on PubMed
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1167. English, Spanish. doi: 10.1016/j.rec.2016.11.005. Erratum in: Rev Esp Cardiol (Engl Ed). 2017 Apr;70(4):309-310. PMID: 27894487.
    See more on PubMed
  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509. Epub 2017 Apr 28. PMID: 28455343.
    See more on PubMed
  • Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194. doi: 10.1016/j.cardfail.2010.04.004. PMID: 20610207.
    See more on PubMed
  • WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5. PMID: 23741058.
    See more on PubMed
  • Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short- term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb;27(3):330-7. doi: 10.1093/eurheartj/ehi631. Epub 2005 Nov 17. PMID: 16293638.
    See more on PubMed
  • Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R, Cano L, González B, Díez C, Pascual T, Elosúa R, Lupón J. Combined use of high- sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012 Jan;14(1):32-8. doi: 10.1093/eurjhf/hfr156. PMID: 22179033.
    See more on PubMed
  • Retnakaran R. Novel Biomarkers for Predicting Cardiovascular Disease in Patients With Diabetes. Can J Cardiol. 2018 May;34(5):624-631. doi: 10.1016/j.cjca.2017.10.017. Epub 2017 Oct 31. PMID: 29287943.
    See more on PubMed
  • Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes- Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? Eur J Heart Fail. 2015 Sep;17(9):936-44. doi: 10.1002/ejhf.320. Epub 2015 Jul 29. PMID: 26222618.
    See more on PubMed

Do you want to learn more?
We're here for you

Please fill in
all fields
marked *
Up
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.
Agree